Funding for this research was provided by:
This work was funded by Palatin Technologies, Inc.
Accepted: 29 September 2021
First Online: 25 October 2021
: This work was funded by Palatin Technologies, Inc.
: John Dodd, Carl Spana, Robert Jordan, Marie Makhlina, Wei Yang, and Keith Barnett are employees of Palatin Technologies, Inc. Luana Pesco Koplowitz and Barry Koplowitz are paid consultants for Palatin Technologies, Inc.
: The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request.
: The study was reviewed and approved by the IntegReview institutional review board and was conducted in accordance with the principles outlined in the Declaration of Helsinki and its amendments.
: All subjects provided written informed consent prior to study participation.
: JD and RJ contributed to the design and oversight of the preclinical and clinical studies. MM contributed to the data handling, design, and oversight of the preclinical studies. LPK and BK provided the pharmacokinetic database, analysis, and report for the clinical study. KB was responsible for clinical operations oversight. WHY contributed to the conception and synthesis of PL8177. CS contributed to the design of preclinical and clinical studies. All authors contributed to manuscript development and reviewed and approved of the final draft.